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ABSTRACT
Background. Previous reports suggest that body compo-
sition parameters can be used to predict outcomes for
patients with gastrointestinal (GI) cancers. However, evi-
dence for an association with long-term survival is
conflicting, with much of the data derived from patients
with advanced disease. This study examined the effect of
body composition on survival in primary operable GI
cancer.
Methods. Patients with resectable adenocarcinoma of the
GI tract (esophagus, stomach, colon, rectum) between 2006
and 2014 were identified from a prospective database.
Computed tomography (CT) scans were analyzed using a
transverse section at L3 to calculate sex-specific body
composition indices for skeletal muscle, visceral fat, and
subcutaneous fat. Kaplan–Meier and log-rank analysis
were used to compare unadjusted survival. Multivariate
survival analyses were performed using a proportional
hazards model.
Results. The study enrolled 447 patients (191 woman and
256 men) with esophagogastric (OG) (n = 108) and col-
orectal (CR) (n = 339) cancer. Body composition did not
predict survival for the OG cancer patients. Among the CR
cancer patients, survival was shorter for those with sar-
copenia (p = 0.017) or low levels of subcutaneous fat
(p = 0.005). Older age (p = 0.046) and neutrophilia
(p = 0.013) were associated with sarcopenia in patients
with CR. Tumor stage (p = 0.033), neutrophil count
(p = 0.011), and hypoalbuminemia (p = 0.023) were
associated with sarcopenia in OG cancer patients. In the
multivariate analysis, no single measure of body compo-
sition was an independent predictor of reduced survival.
Conclusion. Sarcopenia and reduced subcutaneous adi-
posity are associated with reduced survival for patients
with primary operable CR cancer. However, in this study,
no parameter of body composition was an independent
prognostic marker when considered with age, tumor stage,
and systemic inflammation.
An increasing number of reports have suggested that
body composition parameters may be used to predict out-
comes for patients with cancer.1–7 In particular, depletion
of skeletal muscle mass, termed ‘‘sarcopenia,’’ is widely
reported to confer a poor prognosis for patients with tumors
of the gastrointestinal (GI) tract, associated with an
increased rate of postoperative complications2 and
impaired response to chemotherapy.1 A smaller number of
studies also have reported relationships between subcuta-
neous or visceral adiposity and outcomes for several tumor
types, including esophageal,8 pancreatic,9 and colorectal
cancers.10,11 The majority of these studies have used image
analysis of computed tomography (CT) scans to measure
parameters of body composition, and the accuracy of this
technique is now widely accepted.12 This approach has
considerable practical appeal because most patients with
GI cancers undergo CT scanning as part of routine staging.
Despite consistent reports regarding short-term out-
comes, the evidence that body composition parameters
relate to long-term survival for patients with GI cancers has
been conflicting. Studies to date have tended to focus
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exclusively on one parameter of body composition such as
skeletal muscle mass,3,4,6 and much of the survival data has
been derived from small cohorts of patients with locally
advanced or metastatic disease.4,6,7
To investigate this topic further, the current study aimed
to analyze CT-measured parameters of body composition
in a large cohort of patients with primary operable GI
cancers and to examine their relationships with long-term
survival.
METHODS
Patients with confirmed adenocarcinoma of the gas-
trointestinal tract (esophagus, stomach, colon, and rectum)
who underwent surgical resection with curative intent
between 1 January 2006 and 31 December 2014 at
Aberdeen Royal Infirmary were identified from a
prospectively maintained regional database. Of these
patients, only those who had preoperative CT images
stored in an electronic format suitable for image analysis
were included in the study.
All tumors were confirmed histologically and staged
according to conventional American Joint Committee on
Cancer (AJCC) Tumor, Node, and Metastases (TNM)
Classification (6th edition). Additional pathologic data,
including the presence or absence of lymphovascular
invasion, were recorded from reports issued at the time of
resection.
Patient variables recorded retrospectively from medical
records included age, sex, and preoperative blood results
recorded within 30 days before surgery. Using local ref-
erence values, anemia was defined as hemoglobin
concentrations lower than 130 g/L in males and lower than
115 g/L in females. The systemic inflammatory response
was assessed by differential serum white cell count (total
white cell count, neutrophil count, and lymphocyte count)
in line with published thresholds.13,14
The standard oncologic treatment for potentially
resectable esophagogastric (OG) cancers was three cycles
of neoadjuvant combination chemotherapy with epirubicin,
cisplatin and capecitabine (ECX), followed by surgical
resection and adjuvant chemotherapy with the same agents.
Colon cancer was generally managed by surgical resection
followed by adjuvant combination (fluorouracil- and
oxaliplatin-based) chemotherapy for patients with involved
lymph nodes or other pathologic indicators of a poor
prognosis such as extramural venous invasion (EMVI).
Locally advanced or margin-threatened rectal cancer was
treated with ‘‘long course’’ chemoradiotherapy followed by
surgery 8–10 weeks later, with adjuvant chemotherapy
offered selectively for those with a good or partial response
to preoperative treatment. Individual regimens changed
over time and were dependent on patient fitness, inclusion
in contemporary clinical trials, and multidisciplinary team
(MDT) preference.
To perform the body composition analysis, staging
computed tomography (CT) scans were first accessed
through the hospital’s Picture Archiving and Communica-
tion System (PACS). Preoperative staging CTs before the
start of neoadjuvant therapy were selected. A single slice at
the level of the third lumbar vertebra (L3) was analyzed
using medical imaging software (ImageJ; The National
Institutes of Health, Washington, MD, USA; version 1.47),
and the total fat area (cm2), subcutaneous fat area (cm2),
visceral fat area (cm2), and skeletal muscle area (cm2) were
measured using accepted Hounsfield unit (HU) thresholds
(adipose tissue, -190 to -30; skeletal muscle, -29 to
?150). Finally, each parameter was normalized for patient
stature and designated as total fat index (cm2/m2), subcu-
taneous fat index (cm2/m2), visceral fat index (cm2/m2),
and skeletal muscle index (cm2/m2) in line with accepted
methodology.15,16 Sarcopenia was defined as a skeletal
muscle index lower than 43 cm2/m2 for males and lower
than 41 cm2/m2 for females using previously published
cutoff values.6
The primary end point of the study was overall survival,
which was measured in months from the date of surgery to
the date of death from any cause. The date of death was
obtained from patients’ electronic medical records. All
survival analyses were performed after exclusion of 30-day
postoperative deaths. Ethical guidance was sought from the
regional Caldicott Guardian, who confirmed that the study
fulfilled the criteria of a clinical audit, negating the
requirement for further ethical committee approval.
Statistical Analysis
All variables were grouped according to clinically rel-
evant or previously published thresholds. All statistical
tests were two-sided, and a p value lower than 0.05 was
considered to indicate statistical significance. v2 and
Mann–Whitney U tests were used to compare clinical
characteristics between groups. Kaplan–Meier analysis and
the log-rank test were used to compare unadjusted survival
differences. Uni- and multivariate survival analyses were
performed using a Cox proportional hazards model. Sta-
tistical analysis was performed using SPSS, version 22
(SPSS, Chicago, IL, USA).
RESULTS
During the study period, 608 patients with primary
operable gastrointestinal cancers who had undergone sur-
gical resection with curative intent were identified. Of
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these patients, 161 were excluded from the study (108
patients did not have a documented height and weight; 34
patients did not have CT images suitable for analysis; and
19 patients underwent a palliative procedure after more
extensive disease had been diagnosed intraoperatively),
leaving 447 patients (191 women and 256 men) included in
the final analysis. A flow diagram of the study selection
process is shown in Fig. 1.
The baseline clinicopathologic characteristics and body
composition parameters of the cohort are shown in Table 1.
Of the 447 patients included in the study, 108 had eopha-
gogastric (OG) cancers (43 esophageal; 65 gastric), and
339 had colorectal (CR) cancers (253 colonic; 86 rectal).
More than 40% of the patients were anemic preoperatively,
and 18% exhibited a systemic inflammatory response, as
evidenced by an elevated neutrophil count. There were
significant differences between upper GI and colorectal
cancer in terms of age (p\ 0.001), sex (p = 0.003), and
lymphovascular invasion (p\ 0.001).
To account for the differences in body composition
distribution between the men and women, the subcutaneous
fat index and the visceral fat index were classified into sex-
specific tertiles, whereas previously published sex-specific
cutoff values for skeletal muscle index were used to define
sarcopenia in the men (\43 cm2/m2) and the women
(\41 cm2/m2). According to these definitions, 23 patients
(21%) with esophagogastric cancer and 81 patients (24%)
with colorectal cancer showed evidence of sarcopenia on
their staging CT scan (Table 1).
Figure 2 shows the relationships between body compo-
sition parameters and long-term survival. Levels of
subcutaneous fat, visceral fat, and skeletal muscle did not
influence overall survival for the patients with esopha-
gogastric cancer. Among the patients with colorectal
cancer, survival was significantly shorter for those with low
levels of subcutaneous fat (p = 0.005, log-rank test) or
evidence of sarcopenia (p = 0.017, log-rank test).
To investigate these relationships further, the associa-
tions between body composition and clinicopathologic
variables were examined. An association between sar-
copenia and advanced T stage (p = 0.033), elevated
neutrophil count (p = 0.011), and hypoalbuminemia
(p = 0.023) was observed in the patients with esopha-
gogastric cancer (Table 2). In the patients with colorectal
cancer, associations between sarcopenia and older age
(p = 0.046) and elevated neutrophil count (p = 0.026)
were demonstrated. Similar relationships were seen
between low levels of subcutaneous fat and older age
(p\ 0.001) and elevated neutrophil count (p = 0.013)
(Table 3).
Finally, logistic regression analyses were used to
examine whether survival relationships were independent
of established clinicopathologic risk factors. During the
follow-up period, 213 patients died, leaving 234 were alive
All patients 
(N = 608) 
Included in image analysis 
(N = 447) 
CT scan not available 
(N = 34) 
Palliative  
(N = 19) 
Oesophageal  
(N = 43) 
Colonic 
(N = 253) 
No height data  
(N = 108) 
Gastric 
(N = 65) 
Rectal 
(N = 86) 
FIG. 1 Flow diagram showing
patient selection and reasons for
exclusion of patients from the
study
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TABLE 1 Clinical, pathologic, and body composition parameters of the included patients
Variable All patients (n = 447) n (%) OG cancer n (%) CR cancer n (%) p valuea
Age (years)
B65 133 (30) 46 (43) 87 (26) \0.001
65–74 148 (33) 40 (37) 108 (32)
C75 166 (37) 22 (20) 144 (42)
Sex
Female 191 (43) 33 (31) 158 (47) 0.003
Male 256 (57) 74 (69) 181 (53)
Neoadjuvant therapy
No 316 (71) 43 (40) 273 (81) \0.001
Yes 131 (29) 65 (60) 66 (19)
Adjuvant therapy
No 343 (77) 66 (61) 277 (82) \0.001
Yes 104 (23) 42 (39) 62 (18)
TNM stage
1 88 (20) 30 (28) 58 (17) 0.052
2 196 (44) 43 (40) 153 (45)
3 163 (36) 35 (32) 128 (38)
Lymphovascular invasion
Yes 111 (25) 51 (47) 60 (18) \0.001
No 336 (75) 57 (53) 279 (82)
Anemiab,c
Yes 186 (42) 44 (42) 142 (42) 0.873
No 255 (58) 62 (58) 193 (58)
White cell count (9 109/L)c
\8.5 280 (63) 70 (66) 210 (63) 0.711
8.5–11 109 (25) 23 (22) 86 (26)
[11 52 (12) 13 (12) 39 (12)
Neutrophil count (9 109/L)c
\7.5 362 (82) 87 (82) 275 (82) 0.997
C7.5 79 (18) 19 (18) 60 (18)
Lymphocyte count (9 109/L)c
\1.0 94 (21) 18 (17) 76 (23) 0.211
C1.0 347 (79) 88 (83) 259 (77)
Albumin (g/L)c
C35 387 (88) 89 (84) 298 (89) 0.172
\35 54 (12) 17 (16) 37 (11)
Subcutaneous fat index (cm2/m2)
Median 66.2 64.9 70.0 0.114
Range 200.5 193.4 191.9
Low d 152 (34) 38 (35) 114 (34)
Mediumd 148 (33) 33 (31) 115 (34)
Highd 147 (33) 37 (34) 110 (32)
Visceral fat index (cm2/m2)
Median 61.3 63.4 61.0 0.886
Range 198.4 155.0 198.4
Lowe 152 (34) 38 (35) 114 (34)
Mediume 146 (33) 38 (35) 108 (32)
Highd 149 (33) 32 (30) 117 (35)
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at the date of censor (31 March 2015). The median follow-
up period for the survivors was 62 months (range
3–105 months).
In the multivariate analysis, the only independent pre-
dictor of long-term survival for the patients with
esophagogastric cancer was tumor stage [hazard ratio (HR)
2.78; p\ 0.001] (Table 4). For the patients with colorectal
cancer, advanced tumor stage (HR 1.67; p\ 0.001), lym-
phovascular invasion (HR 2.61; p\ 0.001), and elevated
neutrophil count (HR 1.76; p = 0.005) were independently
TABLE 1 continued
Variable All patients (n = 447) n (%) OG cancer n (%) CR cancer n (%) p valuea
Skeletal muscle index (cm2/m2)
Median 47.4 47.7 47.3 0.888
Range 80.1 44.2 80.1
Sarcopeniaf 104 (23) 23 (21) 81 (24)
Normal 343 (77) 85 (79) 258 (76)
OG esophagogastric, CR colorectal, TNM tumor-node-metastasis
a p Values represent X2 tests for a linear trend in categorical variables and Mann–Whitney U tests for continuous variables
b Anemia is defined as\13 g/dL in males,\11.5 g/dL in females
c Data are missing in six cases
d Sex-specific tertiles for subcutaneous fat index
e Sex-specific tertiles for visceral fat index































































































































FIG. 2 The relationships between body composition parameters and
overall survival for patients with primary operable gastrointestinal
cancers. Top panel (left to right): subcutaneous fat index (SFA)
(p = 0.793, log-rank test), visceral fat index (VFA) (p = 0.278, log-
rank test), and skeletal muscle index (SMI; sarcopenia) (p = 0.607,
log-rank test) in esophagogastric cancer. Bottom panel (left to right):
subcutaneous fat index (SFA) (p = 0.005, log-rank test), visceral fat
index (VFA) (p = 0.375, log-rank test), and skeletal muscle index
(SMI; sarcopenia) (p = 0.017, log-rank test) in colorectal cancer
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TABLE 2 Associations between body composition parameters and clinicopathologic variables for patients with esophagogastric cancer


















B64 13 (34) 15 (45) 18 (49) 0.560 20 (53) 14 (37) 12 (38) 0.533 37 (44) 9 (39) 0.744
65–74 16 (42) 10 (30) 14 (38) 11 (29) 17 (45) 12 (38) 32 (38) 8 (35)
C75 9 (24) 8 (24) 5 (14) 7 (18) 7 (18) 8 (25) 16 (19) 6 (26)
Tumour (T) stage
0/1 8 (21) 5 (15) 9 (24) 0.742 6 (16) 7 (18) 9 (28) 0.534 21 (25) 1 (4) 0.033
2 4 (11) 9 (27) 5 (14) 5 (13) 9 (24) 4 (13) 13 (15) 5 (22)
3 22 (58) 17 (52) 20 (54) 23 (61) 18 (47) 18 (56) 47 (55) 12 (52)
4 4 (11) 2 (6) 3 (8) 4 (11) 4 (11) 1 (3) 4 (5) 5 (22)
Nodal (N) stage
0 17 (45) 13 (39) 20 (54) 0.776 13 (34) 15 (39) 22 (69) 0.103 41 (48) 9 (39) 0.362
1 12 (32) 13 (39) 10 (27) 14 (37) 15 (39) 6 (19) 29 (34) 6 (26)
2 9 (24) 7 (21) 7 (19) 11 (29) 8 (21) 4 (13) 15 (18) 8 (35)
TNM stage
I 9 (24) 10 (30) 11 (30) 0.846 6 (16) 11 (29) 13 (41) 0.136 27 (32) 3 (13) 0.175
II 16 (42) 11 (33) 16 (43) 15 (39) 16 (42) 12 (38) 33 (39) 10 (43)
III 13 (34) 12 (36) 10 (27) 17 (45) 11 (29) 7 (22) 25 (29) 10 (43)
Neoadjuvant therapy
Yes 18 (47) 8 (24) 17 (46) 0.090 9 (24) 20 (53) 14 (44) 0.031 34 (40) 9 (39) 0.940
No 20 (53) 25 (76) 20 (54) 29 (76) 18 (47) 18 (56) 51 (60) 14 (61)
Adjuvant therapy
Yes 17 (45) 10 (30) 15 (41) 0.446 18 (47) 13 (34) 11 (34) 0.412 30 (35) 12 (52) 0.141
No 21 (55) 23 (70) 22 (59) 20 (53) 25 (66) 21 (66) 55 (65) 11 (48)
Lymphovascular invasion
Yes 17 (45) 13 (39) 21 (57) 0.324 21 (55) 16 (42) 14 (44) 0.463 38 (45) 13 (57) 0.314
No 21 (55) 20 (61) 16 (43) 17 (45) 22 (58) 18 (56) 47 (55) 10 (43)
Anemiab
Yes 17 (45) 14 (45) 13 (35) 0.621 19 (50) 11 (30) 14 (45) 0.181 33 (39) 11 (50) 0.364
No 21 (55) 17 (55) 24 (65) 19 (50) 26 (70) 17 (55) 51 (61) 11 (50)
White cell count (9109/L)
\8.5 23 (61) 21 (68) 26 (70) 0.840 24 (63) 23 (62) 23 (74) 0.736 61 (73) 9 (41) 0.011
8.5–11 10 (26) 7 (23) 6 (16) 8 (21) 10 (27) 5 (16) 16 (19) 7 (32)
[11 5 (13) 3 (10) 5 (14) 6 (16) 4 (11) 3 (10) 7 (8) 6 (27)
Neutrophil count (9109/L)
\7.5 29 (76) 26 (84) 32 (86) 0.493 30 (79) 31 (84) 26 (84) 0.821 73 (87) 14 (64) 0.011
C7.5 9 (24) 5 (16) 5 (14) 8 (21) 6 (16) 5 (16) 11 (13) 8 (36)
Lymphocyte count (9 109/L)
\1.0 7 (18) 6 (19) 5 (14) 0.781 7 (18) 6 (16) 5 (16) 0.957 14 (17) 4 (18) 0.866
C1.0 31 (82) 25 (81) 32 (86) 31 (82) 31 (84) 26 (84) 70 (83) 18 (82)
Albumin (g/L)
C35 31 (82) 24 (77) 34 (92) 0.238 31 (82) 30 (81) 28 (90) 0.517 74 (88) 15 (68) 0.023
\35 7 (18) 7 (23) 3 (8) 7 (18) 7 (19) 3 (10) 10 (12) 7 (32)
TNM tumor-node-metastasis
a p Values represent X2 tests for a linear trend in categorical variables and Mann–Whitney U tests for continuous variables
b Anemia is defined as\13 g/dL in males,\11.5 g/dL in females
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TABLE 3 The associations between body composition parameters and clinicopathologic variables in patients with colorectal cancer


















B64 25 (22) 23 (20) 39 (35) \0.001 43 (38) 21 (19) 23 (20) \0.001 70 (27) 17 (21) 0.046
65–74 27 (23) 39 (34) 42 (38) 18 (16) 39 (36) 51 (44) 88 (34) 20 (25)
C75 62 (54) 53 (46) 29 (26) 53 (46) 48 (44) 43 (37) 100 (39) 44 (54)
Tumour (T) stage
0/1 9 (8) 5 (4) 8 (7) 0.432 7 (6) 10 (9) 5 (4) 0.219 17 (7) 5 (6) 0.118
2 12 (11) 13 (11) 20 (18) 13 (11) 13 (12) 19 (16) 40 (16) 5 (6)
3 72 (63) 76 (66) 69 (63) 73 (64) 74 (69) 70 (60) 164 (64) 53 (65)
4 21 (18) 21 (18) 13 (12) 21 (18) 11 (10) 23 (20) 37 (14) 18 (22)
Nodal (N) stage
0 69 (61) 65 (57) 77 (70) 0.099 69 (61) 62 (57) 80 (68) 0.482 168 (65) 43 (53) 0.099
1 24 (21) 35 (30) 19 (17) 29 (25) 27 (25) 22 (19) 57 (22) 21 (26)
2 21 (18) 15 (13) 14 (13) 16 (14) 19 (18) 15 (13) 33 (13) 17 (21)
TNM stage
1 19 (17) 13 (11) 26 (24) 0.094 16 (14) 18 (17) 24 (21) 0.398 50 (19) 8 (10) 0.058
2 50 (44) 52 (45) 51 (46) 53 (46) 44 (41) 56 (48) 118 (46) 35 (43)
3 45 (39) 50 (43) 33 (30) 45 (39) 46 (43) 37 (32) 90 (35) 38 (47)
Neoadjuvant therapy
Yes 89 (78) 92 (80) 92 (84) 0.566 88 (77) 88 (81) 97 (83) 0.524 204 (79) 69 (85) 0.225
No 25 (22) 23 (20) 18 (16) 26 (23) 20 (19) 20 (17) 54 (21) 12 (15)
Adjuvant therapy
Yes 15 (13) 22 (19) 25 (23) 0.173 26 (23) 16 (15) 20 (17) 0.281 49 (19) 13 (16) 0.550
No 99 (87) 93 (81) 85 (77) 88 (77) 92 (85) 97 (83) 209 (81) 68 (84)
Lymphovascular invasion
Yes 23 (20) 20 (17) 17 (15) 0.648 20 (18) 18 (17) 22 (19) 0.914 45 (17) 15 (19) 0.825
No 91 (80) 95 (83) 93 (85) 94 (82) 90 (83) 95 (81) 213 (83) 66 (81)
Anemiab
Yes 53 (47) 53 (46) 36 (33) 0.069 49 (44) 44 (41) 49 (42) 0.925 105 (41) 37 (46) 0.423
No 60 (53) 61 (54) 72 (67) 63 (56) 63 (59) 67 (58) 150 (59) 43 (54)
White cell count (9109/L)
\8.5 64 (57) 73 (64) 73 (68) 0.241 76 (68) 64 (60) 70 (60) 0.110 162 (64) 48 (60) 0.561
8.5–11 31 (27) 32 (28) 23 (21) 24 (21) 25 (23) 37 (32) 66 (26) 20 (25)
[11 18 (16) 9 (8) 12 (11) 12 (11) 18 (17) 9 (8) 27 (11) 12 (15)
Neutrophil count (9109/L)
\7.5 83 (73) 99 (87) 93 (86) 0.013 94 (84) 85 (79) 96 (83) 0.669 216 (85) 59 (74) 0.026
C7.5 30 (27) 15 (13) 15 (14) 18 (16) 22 (21) 20 (17) 39 (15) 21 (26)
Lymphocyte count (9109/L)
\1.0 31 (27) 23 (20) 22 (20) 0.334 28 (25) 29 (27) 19 (16) 0.125 57 (22) 19 (24) 0.795
C1.0 82 (73) 91 (80) 86 (80) 84 (75) 78 (73) 97 (84) 198 (78) 61 (76)
Albumin (g/L)
C35 97 (86) 101 (89) 100 (93) 0.275 98 (88) 95 (89) 105 (91) 0.766 229 (90) 69 (86) 0.376
\35 16 (14) 13 (11) 8 (7) 14 (13) 12 (11) 11 (9) 26 (10) 11 (14)
TNM, tumor-node-metastasis
a p values represent X2 tests for a linear trend in categorical variables and Mann–Whitney U tests for continuous variables
b Anemia is defined as\13 g/dL in males,\11.5 g/dL in females
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associated with reduced overall survival (Table 5). No
single measure of body composition was an independent
predictor of reduced survival for patients with primary
operable GI cancer.
DISCUSSION
The results of the current study show that CT measures of
body composition, particularly sarcopenia and reduced levels
of subcutaneous fat, are associated with shorter survival for
patients with primary operable colorectal cancer, but not for
patients with esophagogastric cancer. Furthermore, strong
associations exist between these parameters and other indica-
tors of poor outcome such as advanced age and elevated
systemic inflammatory response. However, when body com-
position parameters were analyzed in a multivariate model, no
single measure was found to have independent predictive value
for patients with either esophagogastric or colorectal cancer.






Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
Age (years)
B65 46 23 (33) 1.148 0.832–1.584 0.402 1.578 1.03–2.417 NS
65–74 40 27 (40)
C75 22 12 (35)
Sex
Female 33 18 (35) 1.026 0.593–1.777 0.926 1.145 0.605–2.167 0.667
Male 75 44 (37)
TNM stage
1 30 5 (14) 2.390 1.681–3.398 \0.001 2.782 1.766–4.382 \0.001
2 43 30 (41)
3 35 27 (44)
Neoadjuvant therapy
Yes 43 20 (32) 1.579 0.926–2.691 0.093 2.111 1.015–4.388 NS
No 65 42 (39)
Adjuvant therapy
Yes 42 23 (35) 0.719 0.429–1.206 0.719 0.403 0.22–0.737 NS
No 66 39 (37)
Lymphovascular invasion
Yes 51 34 (40) 1.722 1.037–2.859 0.036 0.814 0.425–1.560 NS
No 57 28 (33)
Neutrophil count (9109/L)
\7.5 87 48 (36) 1.033 0.549–1.946 0.919 1.048 0.517–2.124 NS
C7.5 19 12 (39)
Subcutaneous fat index (cm2/m2)
High 38 24 (39) 0.912 0.678–1.228 0.545 0.934 0.627–1.39 NS
Medium 33 19 (37)
Low 37 19 (34)
Visceral fat index (cm2/m2)
High 38 26 (41) 0.786 0.571–1.083 0.141 0.738 0.473–1.152 NS
Medium 38 21 (36)
Low 32 15 (32)
Skeletal muscle index (cm2/m2)
Normal 85 48 (36) 1.165 0.642–2.114 0.616 0.761 0.351–1.649 NS
Sarcopenia 23 14 (38)
HR hazard ratio, CI confidence interval, TNM tumor-node-metastasis
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To our knowledge, this is one of the largest studies to
investigate the impact of body composition on long-term
survival of patients with operable GI cancers. Although
associations between sarcopenia and colorectal cancer
outcomes have been reported previously,3,4,6,7,17,18 the
results have been inconsistent. Most previous studies have
included a high proportion of patients with advanced dis-
ease, whereas the current study focused specifically on
patients with operable disease.
A systematic review by Malietzis et al.2 evaluated the
role of body composition in predicting outcomes for
patients with colorectal cancer and concluded that whereas
evidence was consistent that sarcopenia is associated with
poorer short-term outcomes, including excess chemother-
apy toxicity17–19 and an increased risk of surgical
complications,20,21 the evidence for a relationship with
long-term survival was less robust. Indeed, the reviewers
identified only one study of 196 patients, all of whom had






Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p Value
Age (years)
B65 87 36 (29) 1.197 0.976–1.467 0.084 1.099 0.871–1.386 NS
65–74 108 41 (28)
C75 144 74 (34)
Sex
Female 158 74 (32) 0.856 0.622–1.176 0.339 0.994 0.703–1.405 NS
Male 181 77 (30)
TNM stage
1 58 12 (17) 1.921 1.503–2.455 \0.001 1.667 1.263–2.2 \0.001
2 153 64 (29)
3 128 75 (37)
Neoadjuvant therapy
Yes 273 120 (31) 1.095 0.738–1.626 0.651 1.444 0.946–2.203 NS
No 66 31 (32)
Adjuvant therapy
Yes 62 28 (31) 0.979 0.649–1.476 0.976 0.764 0.479–1.218 NS
No 277 123 (31)
Lymphovascular invasion
Yes 60 48 (44) 3.663 2.585–5.190 \0.001 2.606 1.764–3.851 \0.001
No 279 103 (27)
Neutrophil count (9 109/L)
\7.5 275 108 (28) 2.556 1.780–3.669 \0.001 1.760 1.182–2.62 0.005
C7.5 60 41 (41)
Subcutaneous fat index (cm2/m2)
High 114 62 (35) 0.720 0.589–0.880 0.001 0.846 0.662–1.08 NS
Medium 115 52 (31)
Low 110 37 (25)
Visceral fat index (cm2/m2)
High 114 56 (33) 0.873 0.718–1/061 0.172 1.00 0.796–1.256 NS
Medium 108 48 (31)
Low 117 47 (29)
Skeletal muscle index (cm2/m2)
Normal 258 107 (29) 1.527 1.075–2.170 0.018 1.211 0.818–1.795 NS
Sarcopenia 81 44 (35)
HR hazard ratio, CI confidence interval, TNM tumor-node-metastasis
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metastatic disease,7 in which sarcopenia had a detrimental
effect on survival.
Not included in the aforementioned review but widely
referenced as demonstrating the prognostic value of
skeletal muscle depletion for cancer patients, a study by
Martin et al.6 analyzed the body composition parameters of
1473 patients with respiratory and GI cancers. The authors
reported that a predictive model composed entirely of body
composition variables (weight loss, skeletal muscle
depletion, and muscle attenuation) was superior to con-
ventional prognostic markers, including cancer stage.
However, more than 50% of the patients studied had
metastatic disease, and our results suggest that their find-
ings may not be applicable to patients with primary
operable cancers.
It is clear from our own appraisal of the literature and
the conclusions of recent reviews3,4 that the question
whether sarcopenia has prognostic value for patients with
GI malignancies is being hampered by study heterogeneity.
Despite the volume of published work, there still is no
standard definition of CT-based assessments of skeletal
muscle mass.
Although a number of different cutoff values have been
proposed,7,17,22 we chose to use a skeletal muscle index
lower than 43 cm2/m2 for men and lower than 41 cm2/m2
for women to define sarcopenia. These values were pro-
posed by the largest published dataset to document the
body composition of patients with cancer6 and have been
validated in at least one external cohort.7
It must be emphasised that discrepancies in the thresh-
olds used to define sarcopenia have led to considerable
variation in the proportion of patients reported to be
‘‘sarcopenic’’ in the aforementioned studies. For example,
the study by van Vledder et al.,7 using one threshold,
reported that 19% of patients with colorectal liver metas-
tases have sarcopenia, whereas Martin et al.,6 using
different definitions, reported that 53% of women and 31%
of men are sarcopenic. Using the latter definitions, our
levels of sarcopenia were considerably lower (23%), but all
the patients in our cohort were undergoing curative sur-
gery, whereas their study contained a large number of
patients with metastatic disease. Similarly, the assessment
of subcutaneous and visceral adiposity has been undertaken
using a variety of methods including dichotomous cutoff
values,23,24 continuous parameters,25 and visceral-to-sub-
cutaneous ratios.26
Given this variability and with no single method yet
validated, we chose to use sex-specific tertiles to assess
adiposity. It may be that using an alternative technique
would have yielded different results, but we believe our
approach was a rational way of demonstrating any survival
effect.
One noteworthy finding from the current study was the
association between depleted levels of skeletal muscle and
subcutaneous fat and an elevation of the systemic inflam-
matory response in patients with colorectal cancer. The
neutrophil count was used as a marker of systemic
inflammation because findings previously showed it to be
the most reliable prognostic component of the white cell
count.27
In experimental models, pro-inflammatory cytokines
such as interleukin-1 (IL-1), IL-6, and tumor necrosis
factor-a (TNF) have been shown to play a key role in both
anorexia and skeletal muscle proteolysis,28 but the rela-
tionships between systemic inflammation and changes in
body composition in cancer patients are less well under-
stood. Good evidence currently shows that systemic
inflammation is universally associated with poor short- and
long-term outcomes in a variety of solid organ tumor
types,29–31 and an association with skeletal muscle wasting
may offer one explanation for the unfavorable outcomes
observed in sarcopenic patients.14,32,33 In the current study,
despite no significant difference in the prevalence of sar-
copenia between cancer types, a clear relationship was
demonstrated between sarcopenia and survival in colorec-
tal cancer but not in upper GI cancers. Further work is
needed to clarify the relationships between tumor biology,
inflammatory mediators, and parameters of body
composition.
The current study had a number of limitations. The
retrospective nature of the data collection meant that con-
temporary records of patients’ height were missing in a
number of cases. As a result, body composition indices
could not be normalized for stature, thereby limiting the
size of the cohort. Similarly, preoperative weight was
poorly documented in the medical notes, so conventional
parameters of body composition such as body mass index
(BMI) could not be calculated. However, preoperative CT
images were available for almost all the patients, and we
believe that both the size and maturity of the cohort mean
our results are likely to be reliable.
In summary, the current study showed that sarcopenia
and reduced subcutaneous adiposity are associated with
shorter overall survival for patients with primary operable
colorectal cancer. However, no parameter of body com-
position was an independent prognostic marker when
considered with age, tumor stage, and systemic inflam-
matory response. No relationships between body
composition and overall survival were observed in patients
with esophagogastric cancers.
ACKNOWLEDGMENT Professor Graeme Murray, Department
of Pathology, University of Aberdeen provided us access to the col-
orectal cancer pathology databases from which the colorectal
component of the research was based.
D. Black et al.
CONFLICT OF INTEREST There are no conflicts of interest.
REFERENCES
1. Yip C, Dinkel C, Mahajan A, Siddique M, Cook GJR, Goh V.
Imaging body composition in cancer patients: visceral obesity,
sarcopenia and sarcopenic obesity may impact on clinical out-
come. Insights Imaging. 2015;6:489–97.
2. Malietzis G, Aziz O, Bagnall NM, Johns N, Fearon KC, Jenkins
JT. The role of body composition evaluation by computerized
tomography in determining colorectal cancer treatment out-
comes: a systematic review. Eur J Surg Oncol. 2015;41:186–96.
3. Wagner D, DeMarco MM, Amini N, et al. Role of frailty and
sarcopenia in predicting outcomes among patients undergoing
gastrointestinal surgery. World J Gastrointest Surg. 2016;8:27–40.
4. Levolger S, van Vugt JLA, de Bruin RWF, et al. Systematic
review of sarcopenia in patients operated on for gastrointestinal
and hepatopancreatobiliary malignancies. Br J Surg. 2015;102:
1448–58.
5. Veasey Rodrigues H, Baracos VE, Wheler JJ, et al. Body com-
position and survival in the early clinical trials setting. Eur J
Cancer. 2013;49:3068–75.
6. Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the
age of obesity: skeletal muscle depletion is a powerful prognostic
factor, independent of body mass index. J Clin Oncol. 2013;31:
1539–47.
7. van Vledder MG, Levolger S, Ayez N, Verhoef C, Tran TCK,
Ijzermans JNM. Body composition and outcome in patients
undergoing resection of colorectal liver metastases. Br J Surg.
2012;99:550–7.
8. Harada K, Baba Y, Ishimoto T, et al. Low visceral fat content is
associated with poor prognosis in a database of 507 upper gas-
trointestinal cancers. Ann Surg Oncol. 2015;22:3946–53.
9. Balentine CJ, Enriquez J, Fisher W, et al. Intra-abdominal fat
predicts survival in pancreatic cancer. J Gastrointest Surg. 2010;
14:1832–7.
10. Moon HG, Ju YT, Jeong CY, et al. Visceral obesity may affect
oncologic outcome in patients with colorectal cancer. Ann Surg
Oncol. 2008;15:1918–22.
11. Lee CS, Murphy DJ, McMahon C, et al. Visceral adiposity is a risk
factor for poor prognosis in colorectal cancer patients receiving
adjuvant chemotherapy. J Gastrointest Cancer. 2015;46:243–50.
12. Mourtzakis M, Prado CMM, Lieffers JR, et al. A practical and
precise approach to quantification of body composition in cancer
patients using computed tomography images acquired during
routine care. Appl Physiol Nutr Metab. 2008;33:997–1006.
13. Maltoni M, Caraceni A, Brunelli C, et al. Prognostic factors in
advanced cancer patients: evidence-based clinical recommenda-
tions: a study by the Steering Committee of the European
Association for Palliative Care. J Clin Oncol. 2005;23:6240–8.
14. Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-
based prognostic score (mGPS) predicts cancer survival inde-
pendent of tumour site: a Glasgow Inflammation Outcome Study.
Br J Cancer. 2011;104:726–34.
15. Lieffers JR, Bathe OF, Fassbender K, et al. Sarcopenia is associated
with postoperative infection and delayed recovery from colorectal
cancer resection surgery. Br J Cancer. 2012;107:931–6.
16. Reisinger KW, van Vugt JLA, Tegels JJW, et al. Functional
compromise reflected by sarcopenia, frailty, and nutritional
depletion predicts adverse postoperative outcome after colorectal
cancer surgery. Ann Surg. 2015;261:345–52.
17. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and
clinical implications of sarcopenic obesity in patients with solid
tumours of the respiratory and gastrointestinal tracts: a popula-
tion-based study. Lancet Oncol. 2008;9:629–35.
18. Prado CMM, Baracos VE, McCargar LJ, et al. Body composition as
an independent determinant of 5-fluorouracil-based chemotherapy
toxicity. Clin Cancer Res. 2007;13:3264–8.
19. Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-
limiting toxicities and pharmacokinetics of sorafenib in patients
with hepatocellular carcinoma. PLoS One. 2012;7:e37563.
20. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia:
European consensus on definition and diagnosis. Report of the
European Working Group on Sarcopenia in Older People. Age
Ageing. 2010;39:412–23.
21. Jung H-W, Kim JW, Kim J-Y, et al. Effect of muscle mass on
toxicity and survival in patients with colon cancer undergoing
adjuvant chemotherapy. Support Care Cancer. 2015;23:687–94.
22. Fujiwara N, Nakagawa H, Kudo Y, et al. Sarcopenia, intramus-
cular fat deposition, and visceral adiposity predict the outcomes
of hepatocellular carcinoma. J Hepatol. 2015;63:131–140.
23. Watanabe J, Tatsumi K, Mitsuyoshi O, et al. The impact of
visceral obesity on surgical outcomes of laparoscopic surgery for
colon cancer. Int J Colorectal Dis. 2014;29:343–51.
24. Rickles AS, Iannuzzi JC, Mironov O, et al. Visceral obesity and
colorectal cancer: are we missing the boat with BMI? J Gas-
trointest Surg. 2013;17:133–43.
25. Ballian N, Lubner MG, Munoz A, et al. Visceral obesity is
associated with outcomes of total mesorectal excision for rectal
adenocarcinoma. J Surg Oncol. 2012;105:365–70.
26. Clark W, Siegel EM, Chen YA, et al. Quantitative measures of
visceral adiposity and body mass index in predicting rectal cancer
outcomes after neoadjuvant chemoradiation. J Am Coll Surg.
2013;216;1070–81.
27. Watt DG, Martin JC, Park JH, et al. Neutrophil count is the most
important prognostic component of the differential white cell
count in patients undergoing elective surgery for colorectal can-
cer. Am J Surg. 2015;210:24–30.
28. Argile´s JM, Busquets S, Lo´pez-Soriano FJ. The pivotal role of
cytokines in muscle wasting during cancer. Int J Biochem Cell
Biol. 2005;37:2036–46.
29. Fearon KCH. Cancer cachexia and fat-muscle physiology. N Engl
J Med. 2011;365:565–7.
30. Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease:
molecular mechanisms and promising therapies. Nat Rev Drug
Discov. 2015;14:58–74.
31. Vaughan VC, Martin P, Lewandowski PA. Cancer cachexia:
impact, mechanisms, and emerging treatments. J Cachexia Sar-
copenia Muscle. 2013;4:95–109.
32. Roxburgh CSD, McMillan DC. Role of systemic inflammatory
response in predicting survival in patients with primary operable
cancer. Future Oncol. 2010;6:149–63.
33. Richards CH, Roxburgh CSD, MacMillan MT, et al. The rela-
tionships between body composition and the systemic
inflammatory response in patients with primary operable col-
orectal cancer. PLoS One. 2012;7:e41883.
Body Composition in Gastrointestinal Cancer
